Zilbrysq, also known as efgartigimod alfa-fcab, is a medication used to treat generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive [1].
What is Zilbrysq approved for?
Zilbrysq is approved for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies [1].
How does Zilbrysq work?
Zilbrysq is a neonatal Fc receptor (FcRn) blocker. It works by binding to the FcRn receptor, preventing the recycling of IgG antibodies, including pathogenic autoantibodies that cause gMG. This leads to increased degradation of these antibodies and a reduction in their levels in the body [1].
When did Zilbrysq become available?
Zilbrysq received U.S. Food and Drug Administration (FDA) approval on June 20, 2023 [1].
What are the potential side effects of Zilbrysq?
Common side effects reported in clinical trials include hair loss, headache, rash, and tingling or prickling nerve sensations (paresthesia) [1]. It is important to discuss all potential risks and side effects with a healthcare provider.
Where can I find patient support resources for Zilbrysq?
Information and support for patients taking Zilbrysq may be available through the manufacturer's patient support program. Details can typically be found on the drug's official website or by speaking with a healthcare professional [1].
What is the difference between Zilbrysq and Vyvgart?
Zilbrysq and Vyvgart (efgartigimod alfa-scab) are both medications containing efgartigimod alfa. The primary difference lies in their formulation and administration. Zilbrysq is an intravenous (IV) infusion, while Vyvgart is administered subcutaneously (under the skin) [1]. Both are designed to treat gMG by blocking the FcRn receptor.
What is the patent status for Zilbrysq?
Information regarding the patent status and expiration dates for Zilbrysq can be found on specialized resources like DrugPatentWatch.com [2]. Patent exclusivity helps protect the drug manufacturer's investment in research and development.
Who manufactures Zilbrysq?
Zilbrysq is manufactured by Aimmune Therapeutics, Inc., a subsidiary of Nestlé Health Science [1].